Pfizer, migraine

Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal healthcare programs.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT,
Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory framework for crypto assets.
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer Settles $59.7M Medicare Kickback Case Over Biohaven Practices
Pfizer (NYSE:PFE) has agreed to pay $59.7 million to resolve allegations that Biohaven Pharmaceuticals, acquired by Pfizer in October 2022, defrauded Medicare and other healthcare programs by offering kickbacks to
Pfizer settles Biohaven kickback case with DOJ for $60M
Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT. The U.S. Department of Justice alleged Biohaven knowingly caused the submission of false claims to government programs such as Medicare through kickbacks made between
Pfizer CEO: Americans can expect radical change from this upcoming Trump administration
Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.
Is Pfizer Stock a Buy?
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
FiercePharma1d
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
Years-Old List of Alleged Pfizer COVID-19 Vaccine 'Side Effects' Is Misleading
General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...
Pfizer Sells 700 Million Haleon Shares for $3.05 Billion
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...
Cherokee Phoenix2d
OKC Indian Clinic announces contribution from Pfizer to support Native women’s health
Oklahoma City Indian Clinic announced it has received a $250,000 charitable contribution from Pfizer to support programs ...